Stock Market & Financial Investment News

NanoViricides volatility expected to move, FDA 'stands ready' to work on EbolaNanoViricides volatility expected to move as the FDA said it “stands ready” to work with companies and investigators working with patients in “dire need of treatment” for the Ebola virus, Reuters says. Overall option implied volatility of 64 compares to its 26-week average of 79 according to Track Data, suggesting decreasing price movement.

NanoViricides provides quarterly reportNanoViricides filed its quarterly report with the SEC estimating that it now has approximately $36.4M of current assets plus restricted cash as of December 31, 2014. The company's operating expenditure during this quarter was approximately $1.9M. Shareholder equity stood at approximately $30.5M for the quarter. The company reported that all of its drug development programs are progressing satisfactorily and that it will continue to provide updates as appropriate. The company's anti-Ebola nanoviricide drug candidates have been sent for testing at a prestigious BSL4 facility in the .S. The company has the ability to produce sufficient quantities of a successful drug candidate for potential field use. The company estimates that the cash in hand is sufficient to enable initial human clinical trials of injectable FluCide drug candidate, as well as possibly to advance another drug candidate towards initial human clinical trials.